FibroGen (FibroGen) EBIT per Share : $-2.79 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is FibroGen EBIT per Share?

FibroGen's EBIT per Share for the three months ended in Dec. 2023 was $-0.53. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.79.

During the past 3 years, the average EBIT per Share Growth Rate was -9.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was -28.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was -18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for FibroGen's EBIT per Share or its related term are showing as below:

FGEN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -68.1 Med: -9.9 Max: 15.6
Current: -9

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of FibroGen was 15.60% per year. The lowest was -68.10% per year. And the median was -9.90% per year.

FGEN's 3-Year EBIT Growth Rate is ranked worse than
65.03% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs FGEN: -9.00

FibroGen's EBIT for the three months ended in Dec. 2023 was $-51.7 Mil.

FibroGen EBIT per Share Historical Data

The historical data trend for FibroGen's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen EBIT per Share Chart

FibroGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.85

-2.07

-3.12

-3.14

-2.79

FibroGen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.69	-0.79	-0.87	-0.60	-0.53

FibroGen EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

FibroGen's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-271.335	/	97.303
=	-2.79

FibroGen's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-51.699	/	98.509
=	-0.52

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.79

FibroGen (NAS:FGEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

FibroGen EBIT per Share Related Terms

Thank you for viewing the detailed overview of FibroGen's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroGen (FibroGen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

FGEN:Mexico 1FG:Germany 1FG:Germany

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Executives

Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno	director, officer: Chief Executive Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig	officer: Chief Commercial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung	officer: SVP, China Operations	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck	director	C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner	officer: Incoming Chief Medical Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham	officer: Chief Financial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr	director	P O BOX 587, WARSAW IN 46581-0587
Pat Controneo	officer: VP, Finance and CFO	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi	director	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158